{"id":390305,"date":"2019-12-19T00:00:00","date_gmt":"2019-12-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2019-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-29T23:21:37","modified_gmt":"2026-04-29T23:21:37","slug":"dlsfid0001-2019-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfid0001-2019-biopharma-gram-negative-infections-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Gram-Negative Infections | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the launch of antibiotics such as Avycaz \/ Zavicefta, Zerbaxa, Vabomere, Xerava,\u00a0and Zemdri, unmet needs remain for additional effective treatment options. Commercial opportunities exist for emerging therapies with efficacy in patients with drug-resistant infections, especially those associated with high rates of mortality. However, the market is heavily genericized, and cost containment measures may limit commercial success.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the drivers and constraints in the HT-GNI market, and how will the market evolve over the forecast period? How will rising antibiotic resistance rates and the entry of new generics shape the market?<\/li>\n<li>How large are the different GNI indications? What are the resistance rates to different classes of antibiotics across several pathogen species?<\/li>\n<li>How will different emerging therapies targeting antibiotic-resistant pathogens address current unmet needs? What emerging therapies do infectious disease (ID) specialists consider as the most promising, and where will these therapies be used?<\/li>\n<li>What attributes will emerging therapies need to improve on in order to compete with currently marketed products? What challenges will they face?<\/li>\n<\/ul>\n<p><strong>Geographies<\/strong>: United States, EU5, Japan<\/p>\n<p><strong>Primary Research:\u00a0<\/strong>More than 20 country-specific interviews with thought-leading infectious diseases specialists supported by survey data collected for this and other DRG research.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>Diagnosed events of GNIs, segmented by key indications (NP, cSSSIs\/SSIs, BSIs, cIAIs, UTIs), pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.<\/p>\n<p><strong>FORECAST:\u00a0<\/strong>Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2028, segmented by brands \/ generics, geography, and five key indications.<\/p>\n<p><strong>Emerging Therapies:\u00a0<\/strong>Phase III \/ PR: 11\u00a0drugs. Phase II: 4 drugs; coverage of select preclinical and Phase I products<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390305","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390305\/revisions"}],"predecessor-version":[{"id":576563,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390305\/revisions\/576563"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}